Combination therapy
US-10195208-B2 · Feb 5, 2019 · US
Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases
US11780835B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11780835-B2 |
| Application number | US-202117376571-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 15, 2021 |
| Priority date | Aug 30, 2018 |
| Publication date | Oct 10, 2023 |
| Grant date | Oct 10, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of (R)—N-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide having the structure or a pharmaceutically acceptable salt thereof. 2. A method for treating cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of (R)—N-(3-fluoro-4-(3-((1-hydroxypropan-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide having the structure 3. The method of claim 1 , wherein said cancer is selected from cervical cancer, gastrointestinal cancer, esophageal cancer, endometrial cancer, liver cancer, melanoma, Merkel cell carcinoma, lung cancer, head and neck cancer, renal cell carcinoma, and bladder cancer. 4. A method for treating cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of (R)—N-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide having the structure or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of an anti-PD-1 antibody. 5. The method of claim 4 , wherein the anti-PD-1 antibody is pembrolizumab. 6. The method of claim 4 , further comprising administering a therapeutically effective amount of a VEGFR inhibitor. 7. The method of claim 6 , wherein the VEGFR inhibitor is axitinib. 8. The method of claim 5 , further comprising administering a therapeutically effective amount of a VEGFR inhibitor. 9. The method of claim 8 , wherein the VEGFR inhibitor is axitinib.
Assignees
Inventors
Classifications
- C07D471/04Primary
Ortho-condensed systems · CPC title
Antineoplastic agents · CPC title
not condensed and containing further heterocyclic rings · CPC title
not condensed and containing further heterocyclic rings · CPC title
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11780835B2 cover?
- Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
- Who is the assignee on this patent?
- Array Biopharma Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).